Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma Patients

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: BI 1060469 Healthy
Drug: Placebo to BI 1060469
Drug: BI 1060469 asthmatics
Drug: Placebo to BI 1060469 asthmatics

First Posted Date: 2014-04-30

Last Posted Date: 2015-08-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 131

Registration Number: NCT02126865

Locations: 🇩🇪
1333.2.1 Boehringer Ingelheim Investigational Site, Berlin, Germany

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Everolimus
Drug: BI 836845
Drug: Exemestane

First Posted Date: 2014-04-28

Last Posted Date: 2022-02-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 164

Registration Number: NCT02123823

Locations: 🇰🇷
National Cancer Center, Goyang, Korea, Republic of
🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇦🇹
LKH-Univ. Hospital Graz, Graz, Austria

and more 35 locations

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Linagliptin
Drug: Linagliptin/Metformin ER FDC
Drug: Metformin ER

First Posted Date: 2014-04-23

Last Posted Date: 2016-08-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 74

Registration Number: NCT02121509

Locations: 🇩🇪
1288.10.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: empagliflozin high dose
Drug: empagliflozin medium dose
Drug: empagliflozin low dose

First Posted Date: 2014-04-23

Last Posted Date: 2016-09-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 27

Registration Number: NCT02121483

Locations: 🇿🇦
1245.87.27003 Boehringer Ingelheim Investigational Site, Bellville, South Africa
🇿🇦
1245.87.27002 Boehringer Ingelheim Investigational Site, Pretoria, South Africa
🇲🇽
1245.87.52001 Boehringer Ingelheim Investigational Site, Chihuahua, Mexico

and more 8 locations

A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration

Phase 2

Completed

Conditions: Wet Macular Degeneration

Interventions: Drug: BI 144807

First Posted Date: 2014-04-23

Last Posted Date: 2016-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT02121522

Locations: 🇩🇪
1313.20.49003 Boehringer Ingelheim Investigational Site, Tübingen, Germany
🇩🇪
1313.20.49002 Boehringer Ingelheim Investigational Site, Leipzig, Germany
🇩🇪
1313.20.49004 Boehringer Ingelheim Investigational Site, Bonn, Germany

and more 7 locations

Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant Use

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: T80/A5 mg FDC tablet
Drug: T80/A5/H12.5 ng FDC tablet
Drug: H12.5 mg tablet
Drug: T80/A5/H12.5 mg FDC tablet
Drug: H12.5 mf tablet

First Posted Date: 2014-04-23

Last Posted Date: 2017-04-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT02121535

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site, Kanagawa, Yokohama, Japan

A Study to Investigate the Phototoxic Potential of Faldaprevir

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: Faldaprevir high dose
Drug: Faldaprevir low dose
Drug: Placebo
Drug: Ciprofloxacin

First Posted Date: 2014-04-15

Last Posted Date: 2014-06-25

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT02114671

Locations: 🇬🇧
1241.42.44001 Boehringer Ingelheim Investigational Site, Edinburgh, United Kingdom

Relative Bioavailability of Multiple Oral Doses of BI 187004 and Metformin After Co-administration Compared to Multiple Oral Doses of BI 187004 Alone and Metformin Alone in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 187004
Drug: metformin

First Posted Date: 2014-04-10

Last Posted Date: 2016-01-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02109679

Locations: 🇩🇪
1307.7.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 10 mg Empagliflozin/1000 mg Metformin XR
Drug: 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR
Drug: 1 tablet Empagliflozin/2 tablets Metformin XR
Drug: 2 tablets 5 mg Empagliflozin/750 Metformin XR

First Posted Date: 2014-04-08

Last Posted Date: 2017-03-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT02106923

Locations: 🇺🇸
Boehringer Ingelheim Investigational Site, Austin, Texas, United States

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1181181 low dose
Drug: BI 1181181 high dose
Drug: Placebo

First Posted Date: 2014-04-08

Last Posted Date: 2014-07-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02106247

Locations: 🇧🇪
1344.20.32001 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy